Eisai Co. Ltd.
Rank 11 in 2016
Rises 3 places to 8th, taking a place amongst the top ten companies of the Index. Eisai demonstrates particular strength in R&D, engaging in partnerships to develop a comparatively high number of projects that address R&D priorities, and in Donations.
Falls 4 places to 12th lacking board-level responsibility for access and a clear stakeholder engagement process to incorporate local perspectives.
Holds 3rd place, extending ethical standards to third parties, and providing non-sales based incentives for sales agents.
Rises 2 places to 6th, with a clear strategy for engaging in R&D to meet public health needs and 17 projects targeting priority R&D gaps.
Holds 14th place. Below average performance in both registration and pricing with weak outward-facing commitments.
Falls 2 places to 11th, showing strong performance in IP-sharing but peers have broader geographic commitments not to enforce patents.
Rises 3 places to 11th. Average performance with initiatives meeting most good practices standards but none meeting all.
Holds at 4th place. Maintains strong performance in donations with single strong programme committed to eliminate lymphatic filariasis.
Expand process to establish access plans for R&D projects during development. Eisai can improve its process to develop access plans by expanding this process to all projects for diseases in scope and consider the unique requirements needed for each project. It can also establish a firmer timeline for establishing access plans by Phase II of clinical development. This includes developing access plans for projects such as lenvatinib (Lenvima®), an oral medicine which was approved after the period of analysis for the treatment of liver cancer.
Expand registration for epilepsy medicines. Expand access by filing more epilepsy products for registration in countries in scope. Eisai’s products for epilepsy, perampanel (Fycompa®), rufinamide (Inovelon) and zonisamide (Zonegran®), have been filed for registration in three, zero, and one countries, respectively, out of 11 possible priority countries. Additional priority countries for registration can include, Dem. Rep. Congo, Ethiopia, Mozambique, Nigeria, Pakistan, Tanzania and Uganda.
Expand access via voluntary licensing. Eisai can consider terms for voluntary licences of its patented anti-epileptic perampanel (Fycompa®) and any future anti-epileptic medicines. While Fycompa® (perampanel) is not yet first-line or on the 2017 WHO Model List of Essential Medicines (WHO EML), the company is expanding its indications, including for partial onset seizures in children as young as four.
Change since 2016
- Established a process to develop access provisions, including equitable pricing strategies and patent waivers, for projects targeting neglected tropical diseases in countries in scope.
- Extended partnerships with Charles River Laboratories and the Broad Institute to continue developing projects in collaboration that target diseases in scope including malaria.
- Joined Access Accelerated with its Remember I Love You initiative in China. It has also committed to measure impact and share results publicly via Access Observatory.
- Discloses publicly the patent statuses for small molecules in scope via the Pat-INFORMED platform.
- Has publicly committed to the UN Global Compact since 2017.
Pipeline and Portfolio
for diseases and countries in scope
Mid-sized pipeline: 41 R&D projects for diseases in scope (40 medicines; 1 therapeutic vaccine).
Clinical candidates: 28, including eritoran for the treatment of influenza and two Phase II candidates for the treatment of Chagas disease and mycetoma.
Regulatory approvals: 1, perampanel (Fycompa®) for the treatment of partial-onset seizures.
R&D focus: non-communicable diseases (cancer and epilepsy), communicable diseases (malaria) and neglected tropical diseases (e.g. mycetoma).
Access provisions: for 15 projects, most commonly applied through access-oriented partnerships.
Comparatively small portfolio: 15 products for diseases in scope (all medicines).
Portfolio focus: non-communicable diseases (epilepsy).
Essential medicines: 27% of Eisai's medicines are currently listed on the 2017 WHO Model List of Essential Medicines (WHO EML).
First-line treatments: 33% of Eisai's medicines have first-line indications for diseases in scope.
Two business units: Pharmaceuticals and other businesses. Its pharmaceutical business has three areas: prescription pharmaceuticals, consumer healthcare and generic medicines. Its prescription pharmaceutical business has two therapeutic areas: neurology and oncology.
M&A news: No mergers or acquisitions since 2016.
Presence in emerging markets: In 2018, Eisai reports sales in 27 countries in scope; one more than in the 2016 Index. It reports that slightly more than 10% of its sales in 2017 came from China.
* Figure excludes two projects that do not fall into the listed phases of development: e.g., technical lifecycle projects, diagnostics, platform technologies, vector control products, investigator sponsored trials and Phase IV projects.
** Neglected Tropical Diseases, while also communicable, are highlighted separately throughout the Index. See Appendix II.
*** See Appendix IV for definition.
† Data not comparable due to changes in company reporting practices